SCHEMBL2396563

SCHEMBL2396563

c1ccc2[nH]c(-c3nc4ncncc4[nH]3)cc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.57
METAP1 P53582 2/20 0.57
ESR1 P03372 3/20 0.50
CYP19A1 P11511 1/20 0.47
NPY5R Q15761 1/20 0.46
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
GSK3B P49841 1/20 0.41
ITK Q08881 2/20 0.40
KDM4E B2RXH2 3/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
CASP3 P42574 2/20 0.40
KMT2A Q03164 2/20 0.40
SENP8 Q96LD8 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
SENP6 Q9GZR1 2/20 0.40
KDR P35968 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL369485 0.77 METAP2 (0.61) METAP2METAP1NPY5RRAB9ANPC1
SCHEMBL10965168 0.77 METAP2 (0.57) METAP2METAP1CYP19A1NPY5RRAB9A
SCHEMBL680854 0.76 METAP2 (0.65) METAP2METAP1NPY5RRAB9ANPC1
Hydrochloric Acid SCHEMBL10964125 0.75 METAP2 (0.56) METAP2METAP1CYP19A1NPY5RRAB9A
SCHEMBL18486239 0.75 METAP2 (0.56) METAP2METAP1NPY5RRAB9ANPC1
Hydrochloric Acid SCHEMBL4456676 0.75 METAP2 (0.63) METAP2METAP1NPY5RRAB9ANPC1
SCHEMBL467132 0.73 METAP2 (0.57) METAP2METAP1NPY5RRAB9ANPC1
SCHEMBL4924097 0.73 METAP2 (1.00) METAP2METAP1RAB9ANPC1KDM4E
SCHEMBL28221040 0.73 RAB9A (0.53) ESR1CYP19A1RAB9ANPC1GSK3B
SCHEMBL924438 0.73 ESR1 (0.71) METAP2METAP1ESR1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2215090-B1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-03-04 EP disclosed
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 US disclosed
EP-2215090-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-08-11 EP disclosed
WO-2009053716-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS PIK3CA, PIK3CD, PI4KA METAP2 2765/4885METAP1 1769/4885ESR1 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.